SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
-5.07%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$265M
AUM Growth
+$265M
(+6.1%)
Cap. Flow
+$19.6M
Cap. Flow
% of AUM
7.41%
Top 10 Holdings %
Top 10 Hldgs %
65.9%
Holding
29
New
8
Increased
10
Reduced
8
Closed
3
Top Buys
| 1 |
CRGX
CARGO Therapeutics
CRGX
|
$14.1M |
| 2 |
Celcuity
CELC
|
$12.5M |
| 3 |
Disc Medicine
IRON
|
$11.2M |
| 4 |
INZY
Inozyme Pharma
INZY
|
$5.09M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$4.89M |
Top Sells
| 1 |
Merus
MRUS
|
$12.5M |
| 2 |
AnaptysBio
ANAB
|
$8.43M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$8.08M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$4.2M |
| 5 |
Geron
GERN
|
$3.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $27.6M | 10.43% | 64,196 -1,401 | -2% | -$602K |
|
|
2
Disc Medicine
IRON
$2.07B
| $22.7M | 8.57% | 503,089 +248,286 | +97% | +$11.2M |
|
|
3
Crinetics Pharmaceuticals
CRNX
$2.92B
| $21.5M | 8.12% | 479,681 -180,462 | -27% | -$8.08M |
|
4
Vaxcyte
PCVX
$4B
| $16.3M | 6.15% | 215,680 +30,505 | +16% | +$2.3M |
|
5
Ascendis Pharma
ASND
$11.8B
| $15.4M | 5.83% | 113,224 +9,796 | +9% | +$1.34M |
|
6
Cytokinetics
CYTK
$4.23B
| $14.7M | 5.57% | 272,036 +8,335 | +3% | +$452K |
|
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $14.7M | 5.56% | 178,589 +59,401 | +50% | +$4.89M |
|
8
Cogent Biosciences
COGT
$1.69B
| $14.1M | 5.33% | 1,673,919 +78,898 | +5% | +$665K |
|
|
CRGX
9
DELISTED
CARGO Therapeutics
CRGX
| $14.1M | 5.32% | +856,849 | New | +$14.1M |
|
10
KalVista Pharmaceuticals
KALV
$678M
| $13.3M | 5.02% | 1,128,478 -313,474 | -22% | -$3.69M |
|
|
11
Celcuity
CELC
$2.17B
| $12.5M | 4.71% | +760,941 | New | +$12.5M |
|
|
12
Merus
MRUS
$4.98B
| $9.75M | 3.68% | 164,773 -211,856 | -56% | -$12.5M |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.62M | 3.26% | 419,654 +21,657 | +5% | +$445K |
|
|
ABVX
14
Abivax
ABVX
$6.12B
| $8.3M | 3.14% | 627,760 +4,790 | +0.8% | +$63.3K |
|
15
Ironwood Pharmaceuticals
IRWD
$214M
| $7.26M | 2.74% | 1,113,824 +168,912 | +18% | +$1.1M |
|
16
Amicus Therapeutics
FOLD
$2.34B
| $7.08M | 2.67% | 713,536 -184,845 | -21% | -$1.83M |
|
|
17
AnaptysBio
ANAB
$569M
| $6.26M | 2.36% | 249,609 -336,422 | -57% | -$8.43M |
|
18
Phathom Pharmaceuticals
PHAT
$864M
| $6.11M | 2.31% | 593,306 +92,319 | +18% | +$951K |
|
19
iTeos Therapeutics
ITOS
| $5.45M | 2.06% | 367,429 -19,666 | -5% | -$292K |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $5.09M | 1.92% | +1,140,310 | New | +$5.09M |
|
21
Neumora Therapeutics
NMRA
$280M
| $3.83M | 1.45% | +390,084 | New | +$3.83M |
|
22
Enliven Therapeutics
ELVN
$1.2B
| $3.56M | 1.34% | +152,178 | New | +$3.56M |
|
|
LBPH
23
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.93M | 0.73% | +71,442 | New | +$1.93M |
|
|
RAPP
24
Rapport Therapeutics
RAPP
$643M
| $1.63M | 0.62% | +70,000 | New | +$1.63M |
|
|
MORF
25
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.62M | 0.61% | 47,660 -37,972 | -44% | -$1.29M |
|